Early-phase studies have confirmed its safety profile and pharmacokinetic characteristics, paving the way for further evaluation of its therapeutic potential in chronic pain and inflammatory conditions. Professor Péter Mátyus designed SZV-1287 as a dual inhibitor (SSAO and COX) based on a new concept and synthesized it with his team as a new type of anti-inflammatory agent at the Department of Organic Chemistry, Semmelweis University (Budapest, Hungary). The potential effectiveness of SZV-1287 in the treatment of chronic pain was discovered and confirmed by Professor Zsuzsanna Helyes and the detailed preclinical pharmacological studies were carried out with her team under her leadership at the Department of Pharmacology (University of Pécs, Hungary).
TargetEx is proud to have contributed to the early-stage identification of the biological activity of SZV-1287. Our team performed the initial inhibition assays on the semicarbazide-sensitive amine oxidase (SSAO) enzyme, laying the foundation for understanding the compound's unique mechanism of action.
'These pioneering studies provided essential insights into SZV-1287's potential as a novel therapeutic candidate, supporting further preclinical and clinical development.'
We are delighted to see this promising project advance to its current stage of development, with encouraging results that highlight its potential as an effective medicine. The progress of SZV-1287 demonstrates the value of collaborative scientific innovation, and we look forward with optimism to its future impact in healthcare. TargetEx remains committed to contributing to breakthrough research that translates into meaningful therapies for patients worldwide.